Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type:
Application
Filed:
November 3, 2004
Publication date:
March 27, 2008
Inventors:
David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
Abstract: Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus.
Type:
Application
Filed:
May 26, 2010
Publication date:
December 2, 2010
Applicant:
ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
Type:
Grant
Filed:
November 3, 2003
Date of Patent:
October 31, 2006
Assignees:
Diagnostic Hybrids, Inc., Health Research Incorporated
Inventors:
Laura Gillim-Ross, Jill Taylor, David R. Scholl, David E. Wentworth, Joseph D. Jollick
Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
Abstract: The invention relates to diseases of coronaviruses, particularly severe acute respiratory syndrome (SARS). Compositions and methods in connection with peptide-based compounds are described relating to inhibition or prevention of coronavirus activity including that of SARS coronavirus and the ability of its S protein to achieve fusion with and entry into a target cell.
Type:
Application
Filed:
February 14, 2005
Publication date:
January 31, 2008
Applicant:
The Regents of the University of Colorado
Abstract: The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition resulting from a coronavirus such as SARS-CoV.
Type:
Grant
Filed:
November 10, 2005
Date of Patent:
January 31, 2012
Assignee:
Crucell Holland B.V.
Inventors:
Jan Henrik Ter Meulen, Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Jaap Goudsmit
Abstract: The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.
Abstract: This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.
Abstract: This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
Abstract: The present invention relates to polypeptides and proteins useful in the diagnosis and prevention of disease caused by feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FECV).
Type:
Application
Filed:
August 22, 2003
Publication date:
April 1, 2004
Applicant:
Pfizer, Inc.
Inventors:
Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones
Abstract: The present invention relates to polypeptides and proteins useful in the diagnosis and prevention of disease caused by feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FECV).
Type:
Application
Filed:
May 14, 2001
Publication date:
August 22, 2002
Inventors:
Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones
Abstract: The present invention provides a synthetic nucleic acid sequence comprising 10-30 nucleotides of the N gene region and/or the 3′ non-coding region of the SARS-associated coronavirus genome, and a synthetic nucleic acid sequence comprising 10-30 nucleotides of a nucleic acid sequence that is complementary to at least one of those regions. Also provided are compositions comprising the sequences, and uses of the sequences in diagnostic kits. The present invention further provides a primer set for determining the presence or absence of SARS-associated coronavirus in a biological sample, wherein the primer set comprises at least one of the synthetic nucleic acid sequences. Also provided are a composition comprising the primer set, and use of the primer set in a diagnostic kit. Finally, the present invention provides kits and methods for determining the presence or absence of SARS-associated coronavirus in a biological sample.
Type:
Application
Filed:
January 23, 2004
Publication date:
December 30, 2004
Inventors:
Thomas Briese, W. Ian Lipkin, Gustavo Palacios, Omar Jabado
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
Abstract: The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with a novel human coronavirus causing Severe Acute Respiratory Syndrome (SARS). With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of SARS nucleic acid. The oligonucleotide sequences provided with the present invention are located in the replicase gene, the nucleocapsid gene and the 3? end non-coding region of the SARS Coronavirus genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of SARS Coronavirus can be obtained. The oligonucleotide sequences according to the present invention are especially useful in methods for the amplification of nucleic acid.
Type:
Application
Filed:
March 8, 2004
Publication date:
September 10, 2009
Inventors:
P.T.G Sillekens, Marlieke Overdijk, Saskia van de Laar
Abstract: Systems and methods for rapid diagnostics related to the use of CRISPR effector systems and optimized guide sequences for detection of coronavirus, including multiplex lateral flow diagnostic devices and methods of use, are provided.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
September 27, 2022
Assignees:
THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Feng Zhang, Jonathan Gootenberg, Omar Abudayyeh, Julia Joung, Alim Ladha, Han Altae-Tran, Guilhem Faure
Abstract: This invention provides oligonucleotides, reagents and amplification methods for detecting the severe acute respiratory syndrome coronavirus (SARS CoV). This invention also provides related compositions, kits, systems, and computers.
Type:
Grant
Filed:
April 21, 2004
Date of Patent:
May 5, 2009
Assignee:
Genome Institute of Singapore
Inventors:
Ee Chee Ren, Martin L. Hibberd, Lisa Fong Poh Ng
Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.
Type:
Grant
Filed:
July 26, 2010
Date of Patent:
September 16, 2014
Assignee:
Amsterdam Institute of Viral Genomics B.V.
Abstract: The present invention provides a synthetic nucleic acid sequence comprising 10-30 nucleotides of the N gene region and/or the 3? non-coding region of the SARS-associated coronavirus genome, and a synthetic nucleic acid sequence comprising 10-30 nucleotides of a nucleic acid sequence that is complementary to at least one of those regions. Also provided are compositions comprising the sequences, and uses of the sequences in diagnostic kits. The present invention further provides a primer set for determining the presence or absence of SARS-associated coronavirus in a biological sample, wherein the primer set comprises at least one of the synthetic nucleic acid sequences. Also provided are a composition comprising the primer set, and use of the primer set in a diagnostic kit. Finally, the present invention provides kits and methods for determining the presence or absence of SARS-associated coronavirus in a biological sample.
Type:
Grant
Filed:
January 23, 2004
Date of Patent:
September 1, 2009
Assignee:
The Trustees of Columbia University In the City of New York
Inventors:
Thomas Briese, W. Ian Lipkin, Gustavo Palacios, Omar Jabado
Abstract: The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus.